The ASKLEPIOS consortium was funded by the European Commission, under the FP7 program. The goal of ASKLEPIOS was to identify rational targets for the development of novel therapeutic leads against rabies encephalitis by targeting both viral replication and host response. Artemis One Health was involved in the testing of several therapeutic candidates in vitro and in vivo models. Assays such as neutralization, quantitative PCR, viral isolation were routinely used. In addition, the mouse model was refined for studying therapeutic interventions.